A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival
We report the case of a 68-year-old man with advanced hepatocellular carcinoma (HCC) with multiple bone metastases (BM) treated with tyrosine kinase inhibitors. Despite an insufficient disease control on BM with a progression free survival (PFS) of 6 months, sorafenib was not discontinued and multip...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/14/1/5 |
| _version_ | 1827749600131284992 |
|---|---|
| author | Luca Ielasi Bernardo Stefanini Fabio Piscaglia Alessandro Granito Francesco Tovoli |
| author_facet | Luca Ielasi Bernardo Stefanini Fabio Piscaglia Alessandro Granito Francesco Tovoli |
| author_sort | Luca Ielasi |
| collection | DOAJ |
| description | We report the case of a 68-year-old man with advanced hepatocellular carcinoma (HCC) with multiple bone metastases (BM) treated with tyrosine kinase inhibitors. Despite an insufficient disease control on BM with a progression free survival (PFS) of 6 months, sorafenib was not discontinued and multiple radiation therapy (RT) sessions with a palliative purpose were performed. Thanks to this aggressive radiotherapy approach in order to control the bone tumor burden, the patient has continued sorafenib for 34.6 months achieving an overall survival (OS) of 41.3 months. This result highlights the importance of a tailored management of patients with advanced HCC and the role of the RT for BM control, even if at lower cumulative radiation dose, for extending patient survival. |
| first_indexed | 2024-03-11T06:30:52Z |
| format | Article |
| id | doaj.art-4461a0adae1e4b0287205de563e20bae |
| institution | Directory Open Access Journal |
| issn | 2036-7414 2036-7422 |
| language | English |
| last_indexed | 2024-03-11T06:30:52Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj.art-4461a0adae1e4b0287205de563e20bae2023-11-17T11:14:01ZengMDPI AGGastroenterology Insights2036-74142036-74222023-02-01141384410.3390/gastroent14010005A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending SurvivalLuca Ielasi0Bernardo Stefanini1Fabio Piscaglia2Alessandro Granito3Francesco Tovoli4Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, ItalyWe report the case of a 68-year-old man with advanced hepatocellular carcinoma (HCC) with multiple bone metastases (BM) treated with tyrosine kinase inhibitors. Despite an insufficient disease control on BM with a progression free survival (PFS) of 6 months, sorafenib was not discontinued and multiple radiation therapy (RT) sessions with a palliative purpose were performed. Thanks to this aggressive radiotherapy approach in order to control the bone tumor burden, the patient has continued sorafenib for 34.6 months achieving an overall survival (OS) of 41.3 months. This result highlights the importance of a tailored management of patients with advanced HCC and the role of the RT for BM control, even if at lower cumulative radiation dose, for extending patient survival.https://www.mdpi.com/2036-7422/14/1/5hepatocellular carcinomabone metastasesradiotherapysorafenib |
| spellingShingle | Luca Ielasi Bernardo Stefanini Fabio Piscaglia Alessandro Granito Francesco Tovoli A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival Gastroenterology Insights hepatocellular carcinoma bone metastases radiotherapy sorafenib |
| title | A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival |
| title_full | A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival |
| title_fullStr | A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival |
| title_full_unstemmed | A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival |
| title_short | A Case of Advanced Hepatocellular Carcinoma with Bone Metastases Managed with Tyrosine Kinase Inhibitors and Aggressive Palliative Radiation Therapy: Role of Combination Therapy for Extending Survival |
| title_sort | case of advanced hepatocellular carcinoma with bone metastases managed with tyrosine kinase inhibitors and aggressive palliative radiation therapy role of combination therapy for extending survival |
| topic | hepatocellular carcinoma bone metastases radiotherapy sorafenib |
| url | https://www.mdpi.com/2036-7422/14/1/5 |
| work_keys_str_mv | AT lucaielasi acaseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT bernardostefanini acaseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT fabiopiscaglia acaseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT alessandrogranito acaseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT francescotovoli acaseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT lucaielasi caseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT bernardostefanini caseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT fabiopiscaglia caseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT alessandrogranito caseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival AT francescotovoli caseofadvancedhepatocellularcarcinomawithbonemetastasesmanagedwithtyrosinekinaseinhibitorsandaggressivepalliativeradiationtherapyroleofcombinationtherapyforextendingsurvival |